7 January 2025 - Abenacianine is an investigational tumour targeted fluorescent imaging agent that has demonstrated a promising safety profile and the ability to label human lung tumours during surgery.

Vergent Bioscience announced that the US FDA has granted fast track designation for the company’s novel, investigational tumour targeted fluorescent imaging agent, abenacianine for injection (VGT-309), as an adjunct for the intra-operative visualisation of primary lung cancer, other pulmonary lesions, cancer containing lymph nodes, and positive surgical margins in patients undergoing surgery for known or suspected cancer in the lung.

Read Vergent Bioscience press release